Emerging studies suggest this peptide, a dual activator targeting both incretin and glucose-dependent insulinotropic polypeptide , appears to represent a notable step forward for obesity loss . Early patient tests have indicated impressive reductions in abdominal tissue, conceivably surpassing cu